Three-Dimensional Culture Models to Study Innate Anti-Tumor Immune Response: Advantages and Disadvantages
Alessandro Poggi,Federico Villa,Jordi Leonardo Castrillo Fernadez,Delfina Costa,Maria Raffaella Zocchi,Roberto Benelli +5 more
Reads0
Chats0
TLDR
In this article, the properties of 3D tumor culture systems and their use for the study of tumor cell interactions with Natural Killer (NK) cells are discussed. But, the authors do not discuss the differences between the innate immunity of mice and humans.Abstract:
Several approaches have shown that the immune response against tumors strongly affects patients' clinical outcome. Thus, the study of anti-tumor immunity is critical to understand and potentiate the mechanisms underlying the elimination of tumor cells. Natural killer (NK) cells are members of innate immunity and represent powerful anti-tumor effectors, able to eliminate tumor cells without a previous sensitization. Thus, the study of their involvement in anti-tumor responses is critical for clinical translation. This analysis has been performed in vitro, co-incubating NK with tumor cells and quantifying the cytotoxic activity of NK cells. In vivo confirmation has been applied to overcome the limits of in vitro testing, however, the innate immunity of mice and humans is different, leading to discrepancies. Different activating receptors on NK cells and counter-ligands on tumor cells are involved in the antitumor response, and innate immunity is strictly dependent on the specific microenvironment where it takes place. Thus, three-dimensional (3D) culture systems, where NK and tumor cells can interact in a tissue-like architecture, have been created. For example, tumor cell spheroids and primary organoids derived from several tumor types, have been used so far to analyze innate immune response, replacing animal models. Herein, we briefly introduce NK cells and analyze and discuss in detail the properties of 3D tumor culture systems and their use for the study of tumor cell interactions with NK cells.read more
Citations
More filters
Journal ArticleDOI
Natural killer cells and immune-checkpoint inhibitor therapy: Current knowledge and new challenges
TL;DR: In this paper , a review of the most relevant candidates for this role among the variety of potential NK ICs is presented, and the potential relevance of this phenomenon on anti-tumor immune response is discussed.
Journal ArticleDOI
Recent Advances of Organ-on-a-Chip in Cancer Modeling Research
Xingxing Liu,Qiu-lan Su,Xiaoyu Zhang,Wen An Yang,Junhua Ning,Kangle Jia,Jinlan Xin,Huanling Li,Longfei Yu,Yuheng Liao,Diming Zhang +10 more
TL;DR: The organ-on-chip (OoC) platform, which integrates the technology of 3D cell culture, tissue engineering, and microfluidics, is emerging as a new method to simulate the critical structures of the in vivo tumor microenvironment and functional characteristics as discussed by the authors .
Journal ArticleDOI
Photodynamic Therapy-Mediated Immune Responses in Three-Dimensional Tumor Models
Nkune Williams Nkune,Nokuphila Winifred Nompumelelo Simelane,Hanieh Montaseri,Heidi Abrahamse +3 more
TL;DR: Wang et al. as mentioned in this paper summarized the characteristics and techniques for 3D tumor model generation and provided an overview of innate and adaptive immune responses induced by photodynamic therapy in several in vitro and in vivo tumor models.
Journal ArticleDOI
Growth‐rate model predicts in vivo tumor response from in vitro data
TL;DR: In this article , a mathematical model integrating in vitro growth rate inhibition values with pharmacokinetic parameters to estimate in vivo drug response was proposed to better predict how in vitro potency translates into in vivo efficacy.
Journal ArticleDOI
Fibroblasts Impair Migration and Antitumor Activity of NK-92 Lymphocytes in a Melanoma-on-Chip Model
Ilenia Iaia,Virginia Brancato,David Caballero,Rui L. Reis,Massimo Aglietta,Dario Sangiolo,Subhas C. Kundu +6 more
TL;DR: In this paper , a reductionist melanoma-on-a-chip model was proposed to evaluate the essential role of fibroblasts in the antitumor activity of lymphocytes.
References
More filters
Journal ArticleDOI
The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity
Noa Stanietsky,Hrvoje Šimić,Jurica Arapović,Amir Toporik,Ofer Levy,Amit Novik,Zurit Levine,Meirav Beiman,Liat Dassa,Hagit Achdout,Noam Stern-Ginossar,Pinhas Tsukerman,Stipan Jonjić,Ofer Mandelboim +13 more
TL;DR: It is shown that TIGIT is expressed by all human NK cells, that it binds PVR and PVRL2 but not PVRL3 and that it inhibits NK cytotoxicity directly through its ITIM, providing an “alternative self” mechanism for MHC class I inhibition.
Journal ArticleDOI
Of mice and not men: differences between mouse and human immunology
TL;DR: Known discrepancies in both innate and adaptive immunity are outlined, including balance of leukocyte subsets, defensins, Toll receptors, inducible NO synthase, the NK inhibitory receptor families Ly49 and KIR, FcR, Ig subsets andChemokine and chemokine receptor expression.
Book ChapterDOI
Biology of natural killer cells.
TL;DR: The existence of NK cells has prompted a reinterpretation of both the studies of specific cytotoxicity against spontaneous human tumors and the theory of immune surveillance, at least in its most restrictive interpretation.
Journal ArticleDOI
The biology of human natural killer-cell subsets.
TL;DR: Human natural killer cells comprise approximately 15% of all circulating lymphocytes and have the capacity to produce abundant cytokines following activation of monocytes, but has low natural cytotoxicity and is CD16(dim) or CD16(-).
Journal ArticleDOI
High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993
Michael B. Atkins,Michael T. Lotze,Janice P. Dutcher,Richard I. Fisher,Geoffrey R. Weiss,Kim Margolin,Jeff Abrams,M. Sznol,David Parkinson,Michael Hawkins,Carolyn Paradise,Lori Kunkel,Steven A. Rosenberg +12 more
TL;DR: High-dose IL-2 treatment seems to benefit some patients with metastatic melanoma by producing durable CRs or PRs and should be considered for appropriately selected melanoma patients.